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CHEMICALLY INDUCED hepatomas and
sarcomas in the rat are in general moder-
ately immunogenic, so that significant
protection against challenge with viable
tumour cells is afforded to animals
immunized with attenuated tumour or
after resection of tumour (Baldwin, 1973).
In recent studies with an aminoazo-dye-
induced rat hepatoma, D23, it was deter-
mined that the immunogenicity of y-
irradiated cells was abolished by treating
the immunizing cells with agents or pro-
cedures which destroyed, or at least im-
paired, the cells' residual metabolic
activity (Price et al., 1979; Dennick et al.,
1979). These treatments (mild fixation
with glutaraldehyde and maintaining the
cells at temperatures between 41TC and
4500 for 30 min before inoculation) did not
however modify the expression of mem-
brane-associated tumour-specific and allo-
antigens as detected serologically by a
number of test systems. These included
indirect membrane immunofluorescence,
complement-dependent cytotoxicity and
radioisotopic antiglobulin tests, using
appropriate syngeneic and allogeneic sera.
Such findings are in accord with the fact
that isolated rat tumour-antigen prepara-
tions (solubilized tumour-membrane ex-
tracts or plasma-membrane fractions) are
essentiallynon-protective inimmunization
and challenge experiments, even though
they retain tumour-specific antigenic
activity in serological assays (Price &
Baldwin, 1974a, b; Price et al., 1978).
Conversely, acellular antigen prepara-
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tions from a number of chemically in-
duced murine tumours are immunogenic,
and in some cases mice treated with ,ug
quantities of antigen are fully immune to
tumour-cell challenge. This is particularly
exemplified by studies with the 3-methyl-
cholanthrene-induced murine sarcoma,
Meth A (e.g. Natori et al., 1978; Law et al.,
1978). The Meth A sarcoma, originally
obtained from Drs E. A. Boyse and L. J.
Old of the Sloan-Kettering Institute, has
been maintained in the Laboratory of Cell
Biology at the National Cancer Institute,
Bethesda, in ascitic form by serial passage
in BALB/c mice. This tumour, like many
of the chemically induced sarcomas and
hepatomas in the rat, expresses an indi-
vidually distinct tumour-rejection antigen
and a tumour-specific cell-surface antigen
demonstrable serologically with syngeneic
hyperimmune sera (DeLeo et al., 1977).
Also, the ascitic variant of Meth A has
been shown to be free ofmurine leukaemia
virus (MuLV) and MuLV-related antigens
by extensive testing in serum cytotoxicity
assays, the XC plaque assay for ecotropic
virus and the RNA-dependent DNA
polymerase assay. MuLV and its antigens
have been considered to contribute to the
immunogenicity of some murine tumours,
but DeLeo et al. (1977) concluded that
these antigens, which may complicate
serological studies, apparently do not
elicit tumour-transplantation resistance,
otherwise cross-reactions between different
sarcomas would have been much com-
moner.M. R. PRICE, R. G. DENNICK AND L. W. LAW
Since there is this wide difference be-
tween the capacity of antigen prepara-
tions from the Meth A tumour and the
various sarcomas and hepatomas main-
tained in WAB/Not rats, a study was
undertaken to determine whether pro-
cedures which abolished the immuno-
genicity of irradiated rat hepatoma cells
modified the immunogenicity of the Meth
A sarcoma in a similar manner. The results
in Table I demonstrate that under the
conditions of these tests, tumour-specific
rejection reactions against Meth A were
detectable. Immunization of BALB/c
mice with 105 or 106 X-irradiated Meth A
sarcoma cells induced protection against
challenge with 2 x 104 Meth A cells, but
not against 5 x 104 cells from the SV40-
induced sarcoma, mKSA. Protection
against challenge with mKSA cells was
however afforded by immunization with
106 irradiated mKSA cells (Table I).
TABLE I.-Tumour-specific rejection reac-
tions against Meth A and mKSA
sarcoma cells
TABLE II.-Inmunization with glutaralde-
hyde-treated, irradiated Meth A sarcoma
cells
Tumour
Immunization procedure* takes
Untreated controls 7/8
106 IR Meth A cells 0/8
106 IR Meth A cells/0.001% Glut., 30 mint 4/8
106 IR Meth A cells/0.01% Glut., 30 min 2/8
106 IR Meth A cells/0. 1% Glut., 30 min 0/8
* BALB/c mice were immunized with a single s.c.
injection of irradiated tumour cells and challenged
10 days later by s.c. inoculation with 2 x 104 viable
Meth A cells.
t Tumour cells were treated with stated concentra-
tions of glutaraldehyde for 30 min, as described
previously (Price et al., 1979).
tumour cells was essentially equivalent to
that of cells held at 37°C or on ice for 30
min before injection (Table III). In pre-
vious tests, these treatments (glutaralde-
hyde or mild heat) completely abolished
the immunogenicity of irradiated rat
hepatoma D23 cells (Price et al., 1979;
Dennick et al., 1979).
TABLE III.-Immunization with heat-
treated, irradiated MethA sarcoma cells
Immunization
procedure*
Untreated controls
106 IR Meth A cells
105 IR Meth A cells
106 IR mKSA cells
Tumour takes in
mice challenged
with:
Meth A mKSA
(2 x 104 (5 x 104
cells) cells)
7/8 8/8
0/8 8/8
2/8 8/8
6/8 2/8
* BALB/c mice were immunizedwith
a single s.c. injection of irradiated
tumour cells and challenged 10 days
later by s.c. inoculation with viable
tumour cells.
When irradiated Meth A cells were
treated with glutaraldehyde for 30 min,
using concentrations from 0-001% to
0.1%, their capacity to immunize against
viable cell challenge was not significantly
impaired, except perhaps with cells ex-
posed to the lowest concentration (Table
II). Comparably, when 105 or 106 irradi-
ated Meth A cells were maintained at
45°C for 30 min, their capacity to protect
against challenge with 2 x 104 viable
Immunization procedure*
Untreated controls
106 IR Meth A cells/0°C, 30 min
106 IR Meth A cells/37°C, 30 min
106 IR Meth A cells/45°C, 30 min
105 IR Meth A cells/0°C, 30 min
105 IR Meth A cells/37°C, 30 min
105 IR Meth A cells/45°C, 30 min
Tumour
takes
7/8
0/8
2/8
2/8
2/8
1/8
1/8
* BALB/c mice were immunized with a
single s.c. injection of irradiated tumour
cells and challenged 10 days later by s.c.
inoculation with 2 x 104 viable Meth A cells.
These experiments highlight the differ-
ence between the ability of Meth A
sarcoma and the rat hepatomas and
sarcomas to provide immunoprotection
against tumour-cell challenge. This is
further supported by examining the mini-
mum essential conditions for the induction
of tumour immunity. With the rat hepat-
oma D23, for example, 107 irradiated cells
protect against challenge with 103 viable
cells(Price etal., 1979; ratio of immunizing
challenge cells, 10,000:1), whereas with
Meth A only 105 irradiated cells are re-
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quired to elicit resistance to 2 x 104 viable
cells (Tables I and III; ratio ofimmunizing
cells:challenge cells, 5:1). Since the differ-
ence between these 2 ratios is so great,
it would not be expected to be entirely
due to quantitative variations in the num-
ber of antigenic determinants per cell in
rat and murine tumours. A more tenable
explanation is that there is a qualitative
difference between the murine and rat
antigens which may direct the manner in
which they are handled and processed by
the immunized recipient. An attractive
hypothesis is that differences in the pre-
sentation or processing of antigen by
macrophages may account for the present
findings, since it has been proposed that
macrophage-mediated sensitization and
direct sensitization of lymphocytes repre-
sent 2 distinct pathways of induction of
cellular immunity, affecting 2 subpopula-
tions of T-cells (Treves, 1978). This may
contribute to the fact that immunization
with acellular rat-tumour-specific antigens
is accompanied by antibody formation and
sometimes enhancement oftumour growth
(Price & Baldwin, 1974b; Price et al., 1978;
Baldwin et al., 1978), whereas immuno-
protection is the general feature associated
with treatment with murine tumour anti-
gens (Natori et al., 1978; Law et al., 1978).
The extension from these studies is there-
fore to determine whether tumour anti-
gens from the rat are processed differently
from those of their murine-tumour coun-
terparts. It is also important to determine
whether procedures which modify the pro-
cessing of isolated rat tumour antigens
(such as chemical modification, or incor-
poration into the plasma membrane of
metabolically active but non-proliferating
cells) may be accompanied by the acquisi-
tion of a capacity to immunize against a
viable tumour-cell challenge.
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